BeiGene, Ltd/$ONC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BeiGene, Ltd
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Ticker
$ONC
Sector
Trading on
Industry
Biotechnology
Headquarters
Basel, Switzerland
Employees
11,000
ISIN
US07725L1026
Website
BeiGene, Ltd Metrics
BasicAdvanced
$29B
-
-$3.70
0.35
-
Price and volume
Market cap
$29B
Beta
0.35
52-week high
$287.88
52-week low
$174.74
Average daily volume
381K
Financial strength
Current ratio
1.964
Quick ratio
1.645
Long term debt to equity
6.145
Total debt to equity
28.485
Interest coverage (TTM)
-15.99%
Management effectiveness
Return on assets (TTM)
-3.22%
Return on equity (TTM)
-11.44%
Valuation
Price to revenue (TTM)
6.231
Price to book
7.58
Price to tangible book (TTM)
7.69
Price to free cash flow (TTM)
-108.204
Growth
Revenue change (TTM)
51.16%
Earnings per share change (TTM)
-51.11%
3-year revenue growth (CAGR)
68.23%
3-year earnings per share growth (CAGR)
-43.48%
BeiGene, Ltd News
AllArticlesVideos
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
Business Wire·7 hours ago
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA's Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
Business Wire·2 days ago
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
Business Wire·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BeiGene, Ltd stock?
BeiGene, Ltd (ONC) has a market cap of $29B as of June 02, 2025.
What is the P/E ratio for BeiGene, Ltd stock?
The price to earnings (P/E) ratio for BeiGene, Ltd (ONC) stock is 0 as of June 02, 2025.
Does BeiGene, Ltd stock pay dividends?
No, BeiGene, Ltd (ONC) stock does not pay dividends to its shareholders as of June 02, 2025.
When is the next BeiGene, Ltd dividend payment date?
BeiGene, Ltd (ONC) stock does not pay dividends to its shareholders.
What is the beta indicator for BeiGene, Ltd?
BeiGene, Ltd (ONC) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.